Cystic Fibrosis
Summary
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR protein. As a multisystem condition, CF patients show great heterogeneity in presenting clinical symptoms. CF mainly affects the respiratory and gastrointestinal tracts. Three classes of drugs have been used to for treatment in CF patients: inhaled antibiotics for bacterial and fungal respiratory infections, mucolytic drugs for mucociliary clearance of the airways, and pancreatic enzyme replacement therapies (PERTs) for treatment of CF induced exocrine pancreatic insufficiency (EPI). During the last five years, a new class of drugs was launched into the market, specifically treating the underlying cause of CF. These CFTR modulators help restore function of the insufficient CFTR protein. Projects the global cystic fibrosis marketplace to experience tremendous growth during the forecast period. This growth will be driven primarily by the highly anticipated arrival of the CFTR modulator, Vertex Pharmaceuticals' ivacaftor/tezacaftor. Insmed's inhaled antibiotic Arikace (liposomal amikacin) is also expected to launch during the forecast period but is not expected to drive CF market growth as much as the CFTR modulator, since it will be competing with other inhaled antibiotics.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1474113-opportunityanalyzer-cystic-fibrosis-opportunity-analysis-and-forecasts-to-2025
Scope of the Report
- Overview of cystic fibrosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized CF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CF therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Cystic Fibrosis: Executive Summary 9
2.1 CF Transmembrane Conductance Regulator Modulators Expected to Drive Substantial Growth in the Cystic Fibrosis Market from 2015-2025 9
2.2 Licensing Activity and the Formation of New Partnerships Will Steer Small Companies to Continue Research of Novel Compounds 11
2.3 Marketed and Pipeline CF Transmembrane Conductance Regulator Modulators Will Provide Appropriate Treatment for the Majority of the CF Population, but the High Unmet Needs Will Remain 12
2.4 Opportunities Will Remain for the Development of New CF Transmembrane Conductance Regulator Modulators 12
2.5 What Do Physicians Think? 13
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1474113-opportunityanalyzer-cystic-fibrosis-opportunity-analysis-and-forecasts-to-2025
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Summary
Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which codes for the CFTR protein. As a multisystem condition, CF patients show great heterogeneity in presenting clinical symptoms. CF mainly affects the respiratory and gastrointestinal tracts. Three classes of drugs have been used to for treatment in CF patients: inhaled antibiotics for bacterial and fungal respiratory infections, mucolytic drugs for mucociliary clearance of the airways, and pancreatic enzyme replacement therapies (PERTs) for treatment of CF induced exocrine pancreatic insufficiency (EPI). During the last five years, a new class of drugs was launched into the market, specifically treating the underlying cause of CF. These CFTR modulators help restore function of the insufficient CFTR protein. Projects the global cystic fibrosis marketplace to experience tremendous growth during the forecast period. This growth will be driven primarily by the highly anticipated arrival of the CFTR modulator, Vertex Pharmaceuticals' ivacaftor/tezacaftor. Insmed's inhaled antibiotic Arikace (liposomal amikacin) is also expected to launch during the forecast period but is not expected to drive CF market growth as much as the CFTR modulator, since it will be competing with other inhaled antibiotics.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1474113-opportunityanalyzer-cystic-fibrosis-opportunity-analysis-and-forecasts-to-2025
Scope of the Report
- Overview of cystic fibrosis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized CF therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the CF therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global CF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Table of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Cystic Fibrosis: Executive Summary 9
2.1 CF Transmembrane Conductance Regulator Modulators Expected to Drive Substantial Growth in the Cystic Fibrosis Market from 2015-2025 9
2.2 Licensing Activity and the Formation of New Partnerships Will Steer Small Companies to Continue Research of Novel Compounds 11
2.3 Marketed and Pipeline CF Transmembrane Conductance Regulator Modulators Will Provide Appropriate Treatment for the Majority of the CF Population, but the High Unmet Needs Will Remain 12
2.4 Opportunities Will Remain for the Development of New CF Transmembrane Conductance Regulator Modulators 12
2.5 What Do Physicians Think? 13
.Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1474113-opportunityanalyzer-cystic-fibrosis-opportunity-analysis-and-forecasts-to-2025
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
No comments:
Post a Comment